EP Patent

EP1725234A4 — TREATMENT WITH LOW ADVERSE EFFECTS AGAINST DISEASES RELATED TO HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA

Assigned to University of Pennsylvania Penn · Expires 2009-04-15 · 17y expired

What this patent protects

Patent listed against lomitapide-mesylate.

Drugs covered by this patent

lomitapide-mesylate (LOMITAPIDE MESYLATE)

Patent Metadata

Patent number: EP1725234A4
Jurisdiction: EP
Classification: —
Expires: 2009-04-15
Drug substance claim: No
Drug product claim: No
Assignee: University of Pennsylvania Penn
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.